Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes

INTRODUCTION: To examine the utility of sequential versus dual add-on approaches in patients who have type 2 diabetes and inadequate glycemic control with metformin therapy alone, we characterized the efficacy and safety of dual therapy with dapagliflozin or saxagliptin added to metformin in the ope...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathieu, Chantal, Catrinoiu, Doina, Ranetti, Aurelian Emil, Johnsson, Eva, Hansen, Lars, Chen, Hungta, Garcia-Sanchez, Ricardo, Iqbal, Nayyar, Celiñski, Aleksander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064585/
https://www.ncbi.nlm.nih.gov/pubmed/29802530
http://dx.doi.org/10.1007/s13300-018-0445-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064585/
https://www.ncbi.nlm.nih.gov/pubmed/29802530
http://dx.doi.org/10.1007/s13300-018-0445-x

Ejemplares similares